ArticleACS medicinal chemistry letters2021
Promising Non-cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B.
Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Development of 1-(substituted benzofuran-2-yl)-3-(halogen-substituted phenyl)prop-2-en-1-ones as potent, reversible, and selective MAO-B inhibitors for Parkinson's Disease.Scientific reports · 2026Article
- Novel Insights on Benzo[Antioxidants (Basel, Switzerland) · 2026Article
- Article
- The discovery of monoamine oxidase inhibitors: virtual screening and in vitro inhibition potencies.Journal of computer-aided molecular design · 2026Article
- Microwave-assisted synthesis of 2'-hydroxychalcone derivatives in 1-decyl-3-methylimidazolium bromide ionic liquid and its computational study.Royal Society open science · 2025Article
- Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson's Disease: An Update.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Inhibition of monoamine oxidases and neuroprotective effects: chalcones vs. chromones.Molecular diversity · 2025Article
- Development of 5-phenylnitro bearing furan-based chalcones as a new class of potent MAO-B inhibitors.Future medicinal chemistry · 2025Article
- Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012-2024).Molecules (Basel, Switzerland) · 2024Review
- Hybrid Metal Catalysts as Valuable Tools in Organic Synthesis: An Overview of the Recent Advances in Asymmetric C─C Bond Formation Reactions.Molecules (Basel, Switzerland) · 2024Review
- Synthesis and Monoamine Oxidase Inhibitory Activity of Halogenated Flavones.ACS medicinal chemistry letters · 2024Article
- A Comprehensive Review of the Docking Studies of Chalcone for the Development of Selective MAO-B Inhibitors.CNS & neurological disorders drug targets · 2024Review
- Targeting Ovarian Cancer with Chalcone Derivatives: Cytotoxicity and Apoptosis Induction in HGSOC Cells.Molecules (Basel, Switzerland) · 2023Article
- Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Chalcones as Potential Ligands for the Treatment of Parkinson's Disease.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Chemoinformatics Analyses of Tau Ligands Reveal Key Molecular Requirements for the Identification of Potential Drug Candidates against Tauopathies.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A library of monosubstituted chalcones (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.